Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,941 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.
Geschwind JF, Kudo M, Marrero JA, Venook AP, Chen XP, Bronowicki JP, Dagher L, Furuse J, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Ye SL, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R. Geschwind JF, et al. Among authors: nakajima k. Radiology. 2016 May;279(2):630-40. doi: 10.1148/radiol.2015150667. Epub 2016 Jan 8. Radiology. 2016. PMID: 26744927
First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study.
Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Cihon F, Heldner S, Marrero JA. Lencioni R, et al. Among authors: nakajima k. Int J Clin Pract. 2012 Jul;66(7):675-83. doi: 10.1111/j.1742-1241.2012.02940.x. Int J Clin Pract. 2012. PMID: 22698419 Free article.
GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.
Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ. Lencioni R, et al. Among authors: nakajima k. Int J Clin Pract. 2014 May;68(5):609-17. doi: 10.1111/ijcp.12352. Epub 2013 Nov 28. Int J Clin Pract. 2014. PMID: 24283303 Free PMC article. Clinical Trial.
Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study.
Kudo M, Lencioni R, Marrero JA, Venook AP, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Ye SL. Kudo M, et al. Among authors: nakajima k. Liver Int. 2016 Aug;36(8):1196-205. doi: 10.1111/liv.13096. Epub 2016 Apr 1. Liver Int. 2016. PMID: 26901163
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.
Marrero JA, Kudo M, Venook AP, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JH, de Guevara LL, Papandreou C, Takayama T, Sanyal AJ, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R. Marrero JA, et al. Among authors: nakajima k. J Hepatol. 2016 Dec;65(6):1140-1147. doi: 10.1016/j.jhep.2016.07.020. Epub 2016 Jul 25. J Hepatol. 2016. PMID: 27469901
Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study.
Ye SL, Chen X, Yang J, Bie P, Zhang S, Liu F, Liu L, Zhou J, Dou K, Hao C, Shao G, Xia Q, Chen Y, Yang J, Deng X, Liu Y, Yuan Y, Fu Z, Nakajima K, Yip CS, Lu Z. Ye SL, et al. Among authors: nakajima k. Oncotarget. 2016 Feb 9;7(6):6639-48. doi: 10.18632/oncotarget.6781. Oncotarget. 2016. PMID: 26735891 Free PMC article. Clinical Trial.
4,941 results